Ax­some clears Phase 3 in nar­colep­sy; Nkar­ta eyes $240M raise

Plus, news about AriBio, Fer­rer, Verge Ge­nomics, Ther­at­e­ch­nolo­gies and BioX­cel Ther­a­peu­tics:

Ax­some re­ports late-phase da­ta in nar­colep­sy: The biotech’s AXS-12 (re­box­e­tine)

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER